Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $17.1667.

A number of research firms have recently commented on ALT. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Citigroup reissued a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Citizens Jmp lowered their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Friday, November 7th. Barclays initiated coverage on Altimmune in a research report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Monday, October 20th.

Altimmune Price Performance

Shares of NASDAQ ALT opened at $4.65 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18. The firm has a fifty day moving average of $4.66 and a 200 day moving average of $4.20. The firm has a market cap of $524.66 million, a PE ratio of -4.35 and a beta of 0.09. Altimmune has a one year low of $2.90 and a one year high of $7.73.

Insider Transactions at Altimmune

In other Altimmune news, Director John Gill purchased 12,500 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were purchased at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the transaction, the director owned 12,500 shares of the company’s stock, valued at $51,250. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jerome Benedict Durso acquired 12,500 shares of the business’s stock in a transaction on Monday, December 22nd. The stock was acquired at an average price of $4.13 per share, with a total value of $51,625.00. Following the acquisition, the director owned 12,500 shares in the company, valued at $51,625. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 30,527 shares of company stock worth $125,278 over the last 90 days. 4.40% of the stock is currently owned by company insiders.

Institutional Trading of Altimmune

Hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. lifted its position in shares of Altimmune by 27.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after purchasing an additional 1,928 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Altimmune during the 3rd quarter worth approximately $38,000. BNP Paribas Financial Markets lifted its holdings in Altimmune by 108.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after buying an additional 5,253 shares in the last quarter. Prudential Financial Inc. purchased a new position in Altimmune in the 2nd quarter valued at approximately $43,000. Finally, Sequoia Financial Advisors LLC acquired a new position in shares of Altimmune in the third quarter worth $46,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.